Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Products under Development by Stage of Development | 8 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Products under Development by Therapy Area | 9 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Products under Development by Indication | 10 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Products under Development by Companies | 12 | 2 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Products under Development by Universities/Institutes | 14 | 2 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 2 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Companies Involved in Therapeutics Development | 21 | 8 |
| Aurigene Discovery Technologies Limited | 21 | 1 |
| Boehringer Ingelheim GmbH | 22 | 1 |
| Horizon Discovery Group Plc | 23 | 1 |
| Nimbus Therapeutics, LLC | 24 | 1 |
| Nuevolution AB | 25 | 1 |
| PeptiDream Inc. | 26 | 1 |
| Tosk, Inc. | 27 | 1 |
| Warp Drive Bio, Inc. | 28 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Drug Profiles | 29 | 17 |
| ARS-853 Drug Profile | 29 | 1 |
| AZD-4785 Drug Profile | 30 | 1 |
| HD-001 Drug Profile | 31 | 1 |
| MM-41 Drug Profile | 32 | 1 |
| Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer Drug Profile | 33 | 1 |
| Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer Drug Profile | 34 | 1 |
| Small Molecule to Inhibit KRAS for Oncology Drug Profile | 35 | 1 |
| Small Molecules 1 to Inhibit K-Ras for Oncology Drug Profile | 36 | 1 |
| Small Molecules 2 to Inhibit K-Ras for Oncology Drug Profile | 37 | 1 |
| Small Molecules 3 to Inhibit Ki-Ras for Oncology Drug Profile | 38 | 1 |
| Small Molecules to Inhibit K-Ras for Oncology Drug Profile | 39 | 1 |
| Small Molecules to Inhibit K-Ras for Oncology Drug Profile | 40 | 1 |
| Small Molecules to Inhibit KRAS for Oncology Drug Profile | 41 | 1 |
| Small Molecules to Inhibit KRas for Solid Tumor Drug Profile | 42 | 1 |
| Small Molecules to Inhibit KRAS2B for Oncology Drug Profile | 43 | 1 |
| SML-8731 Drug Profile | 44 | 1 |
| Vaccine to Target K-RAS for Lung Cancer Drug Profile | 45 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Dormant Projects | 46 | 1 |
| GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Featured News &Press Releases | 47 | 2 |
| Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation | 47 | 1 |
| May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement | 47 | 2 |
| Appendix | 49 | 2 |
| Methodology | 49 | 1 |
| Coverage | 49 | 1 |
| Secondary Research | 49 | 1 |
| Primary Research | 49 | 1 |
| Expert Panel Validation | 49 | 1 |
| Contact Us | 49 | 1 |
| Disclaimer | 50 | 1 |
